Adjuvant radiotherapy for completely resected stage 2 thymoma

Area of Science:

• Thoracic Surgery
• Radiation Oncology
• Oncology

Background:

• The role of postoperative mediastinal radiation in completely resected Masaoka stage 2 thymoma is debated.
• The indolent nature and low recurrence rates of thymoma complicate determining the optimal treatment approach.

Purpose of the Study:

• To evaluate the clinical benefit of adjuvant radiotherapy in patients with completely resected Masaoka stage 2 thymoma.
• To compare local recurrence rates between patients treated with resection alone versus resection plus adjuvant radiotherapy.

Main Methods:

• Retrospective review of 175 patients who underwent thymic resection (1990-2008).
• Focus on 62 patients with completely resected Masaoka stage 2 thymoma, comparing 37 who received adjuvant radiotherapy to 25 who were observed.
• Primary endpoint was local recurrence; patients with high recurrence risk were referred for radiotherapy.

Main Results:

• The local recurrence rate was 3.2% overall.
• Recurrence occurred in 8% of observed patients versus 0% of those receiving adjuvant radiotherapy (P = .15).
• No significant difference in recurrence was observed; adjuvant radiotherapy was well-tolerated with no grade 3 or 4 complications.

Conclusions:

• Both resection alone and resection with adjuvant radiotherapy resulted in low recurrence rates for stage 2 thymoma.
• Adjuvant radiotherapy did not significantly decrease local relapse rates in this cohort.
• Future studies should investigate higher-risk patients based on resection completeness, histology, and tumor size.